Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5 | $0 | $0 | $0 |
| Gross Profit | -$5 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41 | $39 | $52 | $46 |
| G&A Expenses | $12 | $15 | $19 | $17 |
| SG&A Expenses | $12 | $15 | $19 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $53 | $54 | $71 | $63 |
| Operating Income | -$58 | -$54 | -$71 | -$63 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $3 | $4 |
| Pre-Tax Income | -$57 | -$53 | -$68 | -$59 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$57 | -$53 | -$68 | -$59 |
| % Margin | – | – | – | – |
| EPS | -0.35 | -0.33 | -0.42 | -0.37 |
| % Growth | -6.1% | 21.4% | -13.5% | – |
| EPS Diluted | -0.35 | -0.33 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 162 | 162 | 161 | 161 |
| Weighted Avg Shares Out Dil | 162 | 162 | 161 | 161 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $4 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$56 | -$54 | -$71 | -$63 |
| % Margin | – | – | – | – |